Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.
J Neurosurg. 2011 Apr;114(4):1021-7. doi: 10.3171/2010.9.JNS10445. Epub 2010 Oct 15.
Intracranial stenting has improved the ability to treat wide-neck aneurysms via endovascular techniques. However, stent placement necessitates the use of antiplatelet agents, and the latter may complicate the treatment of patients with acutely ruptured aneurysms who demonstrate hydrocephalus and require ventriculostomy. Antiplatelet agents in this setting could increase the incidence of ventriculostomy-related hemorrhagic complications, but there are insufficient data in the medical literature to quantify this potential risk. The aim of this study was to directly quantify the risk of ventriculostomy-related hemorrhage in patients with acute aneurysmal subarachnoid hemorrhage treated with stent-assisted coiling.
The authors retrospectively identified 131 patients who underwent endovascular treatment for an acutely ruptured aneurysm as well as ventriculostomy or ventriculoperitoneal (VP) shunt placement. The rate of hemorrhagic complications associated with ventriculostomy or VP shunt insertion was compared between patients who underwent coiling without a stent (Group 1) and those who underwent stent-assisted coiling and dual antiplatelet therapy (Group 2).
One hundred nine ventriculostomies or VP shunt placement procedures were performed in 91 patients in Group 1, and 50 procedures were undertaken in 40 patients in Group 2. The rates of radiographic hemorrhage and symptomatic hemorrhage were significantly higher in Group 2 (32% vs 14.7%, p = 0.02; and 8% vs 0.9%, p = 0.03, respectively). On multivariate analyses, Group 2 had 3.42 times the odds of a radiographic hemorrhage (95% CI 1.46-8.04, p = 0.0048) after adjusting for antiplatelet use prior to admission.
The application of dual antiplatelet therapy in stent-assisted coiling of acutely ruptured aneurysms is associated with an increase in the risk of hemorrhagic complications following ventriculostomy or VP shunt placement, as compared with its use in a coiling procedure without a stent.
颅内支架置入术通过血管内技术提高了治疗宽颈动脉瘤的能力。然而,支架置入需要使用抗血小板药物,而后者可能会使伴有脑积水并需要脑室造口术的急性破裂动脉瘤患者的治疗复杂化。在这种情况下,抗血小板药物可能会增加脑室造口术相关出血并发症的发生率,但医学文献中没有足够的数据来量化这种潜在风险。本研究旨在直接量化支架辅助弹簧圈治疗急性破裂蛛网膜下腔出血患者行脑室造口术相关出血的风险。
作者回顾性地确定了 131 例接受血管内治疗的急性破裂动脉瘤患者,以及脑室造口术或脑室-腹腔(VP)分流术。比较了未行支架置入的弹簧圈治疗(1 组)和支架辅助弹簧圈治疗及双联抗血小板治疗(2 组)患者的脑室造口术或 VP 分流术相关出血并发症发生率。
在 1 组的 91 例患者中进行了 109 次脑室造口术或 VP 分流术,在 2 组的 40 例患者中进行了 50 次。2 组的影像学出血和症状性出血发生率显著较高(32%比 14.7%,p=0.02;8%比 0.9%,p=0.03)。多变量分析显示,调整入院前抗血小板药物使用后,2 组影像学出血的优势比为 3.42(95%可信区间 1.46-8.04,p=0.0048)。
与单纯弹簧圈治疗相比,支架辅助弹簧圈治疗急性破裂动脉瘤时应用双联抗血小板治疗与脑室造口术或 VP 分流术后出血并发症风险增加相关。